post transplant maintenance therapy
Showing 1 - 25 of >10,000
Multiple Myeloma Trial in Houston (Isatuximab, lenalidomide)
Not yet recruiting
- Multiple Myeloma
-
Houston, TexasM D Anderson Cancer Center
Mar 8, 2023
Myeloid Malignancy, Acute Myeloid Leukemia Trial in Cleveland (Venetoclax, Decitabine)
Not yet recruiting
- Myeloid Malignancy
- Acute Myeloid Leukemia
-
Cleveland, OhioUniversity Hospitals Seidman Cancer, Case Comprehensive Cancer C
Nov 8, 2023
Multiple Myeloma Trial (Iberdomide, Daratumumab/rHuPH20 Co-formulation)
Not yet recruiting
- Multiple Myeloma
- Iberdomide
- Daratumumab/rHuPH20 Co-formulation
- (no location specified)
Oct 25, 2023
Based on Maintenance Therapy Post Autologous Stem Cell
Recruiting
- Multiple Myeloma
- Autologous Stem Cell Transplant
- +2 more
-
Tampa, FloridaMoffitt Cancer Center
Jul 27, 2022
Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Duarte (procedure, drug, biological, other)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Allogeneic Hematopoietic Stem Cell Transplantation
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
Apr 10, 2023
Relapsed Diffuse Large B-cell Lymphoma Trial in Detroit (loncastuximab tesirine)
Recruiting
- Relapsed Diffuse Large B-cell Lymphoma
- loncastuximab tesirine
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
Jun 24, 2022
Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma Trial in Houston (biological, drug, other)
Active, not recruiting
- Hematopoietic Cell Transplantation Recipient
- Plasma Cell Myeloma
- Elotuzumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Feb 2, 2022
Multiple Myeloma Trial in Chicago (Screening Phase, Discontinuation Phase)
Recruiting
- Multiple Myeloma
- Screening Phase
- Discontinuation Phase
-
Chicago, IllinoisUniversity Of Chicago Medicine Comprehensive Cancer Center
Jan 8, 2021
Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma Trial in Houston (Ixazomib Citrate, Lenalidomide,
Active, not recruiting
- Hematopoietic Cell Transplantation Recipient
- Plasma Cell Myeloma
- Ixazomib Citrate
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Mar 8, 2022
Leukemia, Myeloid, Acute Trial in Guanzhou (Azacitidine, Chidamide)
Recruiting
- Leukemia, Myeloid, Acute
-
Guanzhou, Guandong, ChinaNanfang Hospital of Southern Medical University
Mar 6, 2022
Multiple Myeloma, Myeloma-Associated Amyloidosis Trial in Saint Louis (Selinexor, Lenalidomide, Dexamethasone)
Not yet recruiting
- Multiple Myeloma
- Myeloma-Associated Amyloidosis
- Selinexor
- +2 more
-
Saint Louis, MissouriWashington University School of Medicine
Apr 6, 2023
Myeloproliferative Tumor Trial in Tampa (Fedratinib Pill)
Recruiting
- Myeloproliferative Neoplasm
- Fedratinib Pill
-
Tampa, FloridaMoffitt Cancer Center
Nov 28, 2022
Plasma Cell Myeloma, Transplant-Related Carcinoma Trial in Seattle (Ixazomib Citrate, Laboratory Biomarker Analysis,
Active, not recruiting
- Plasma Cell Myeloma
- Transplant-Related Carcinoma
- Ixazomib Citrate
- +2 more
-
Seattle, WashingtonFred Hutchinson Cancer Research Center
Jul 12, 2022
Myeloma Trial in Philadelphia (Belantamab mafodotin)
Recruiting
- Myeloma
- Belantamab mafodotin
-
Philadelphia, PennsylvaniaAbramson Cancer Center at University of Pennsylvania
Jun 13, 2022
Acute Myelogenous Leukemia AML, Myelodysplastic Syndrome MDS Trial in Maywood (Vidaza and Valproic Acid)
Recruiting
- Acute Myelogenous Leukemia AML
- Myelodysplastic Syndrome MDS
- Vidaza and Valproic Acid
-
Maywood, IllinoisLoyola University Cardinal Bernardin Cancer Center
Apr 23, 2021
MDS (MDS), Acute Myelogenous Leukemia (AML) Trial in United States (low dose 5'-azacitidine)
Active, not recruiting
- Myelodysplastic Syndromes (MDS)
- Acute Myelogenous Leukemia (AML)
- low dose 5'-azacitidine
-
Basking Ridge, New Jersey
- +6 more
Dec 1, 2022
Multiple Myeloma Trial in Omaha (Iberdomide)
Recruiting
- Multiple Myeloma
-
Omaha, NebraskaUniversity of Nebraska Medical Center
Apr 27, 2022
Post-transplant Lymphoproliferative Disorder Trial in Saint Louis (Polatuzumab vedotin, Rituximab, CHP)
Not yet recruiting
- Post-transplant Lymphoproliferative Disorder
- Polatuzumab vedotin
- +2 more
-
Saint Louis, MissouriWashington University School of Medicine
Sep 9, 2023
Renal Transplant Rejection, Induction Therapy Trial (Rabbit Anti thymocyte globulin (rATG), Basiliximab)
Not yet recruiting
- Renal Transplant Rejection
- Induction Therapy
- Rabbit Anti thymocyte globulin (rATG)
- Basiliximab
- (no location specified)
Sep 22, 2022